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Abstract
Two glycosylated flavonoids, the quercetin-3-O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside and myricetin-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside, were isolated from the  CH2Cl2/MeOH fraction of Syzygium jambos (L.) Alston, 
Myrtaceae. The structures of these compounds were elucidated by spectroscopic means. The cytotoxicity of the compounds 
was evaluated against the RAW 264.7 cell lines by the lactate dehydrogenase assay. All analyzed compounds were less cyto-
toxic than the positive control (actinomycin D,  CC50 = 0.008 μM). The anti-inflammatory and anti-arthritic activities were 
evaluated by measuring inflammatory parameters in murine models. The two glycosylated flavonoids inhibited the production 
of tumor necrosis factor-α in RAW 264.7 cell line with  IC50 of 1.68 and 1.11 μM, respectively. In addition, all flavonoids 
decreased the levels of tumor necrosis factor-α, C-reactive protein, and fibrinogen at a dose of 5 mg/kg in murine models.
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Introduction
Inflammation is a response of self-protection from the body 
against the harmful agents that are involved in damaging the 
cells, tissues, and organs (Kuprash and Nedospasov 2016). 
Inflammation is providing assistance to the body to get rid 
of harmful agents, and injured tissue components, so that 
the body can begin to heal (Kuprash and Nedospasov 2016). 
During an inflammatory reaction swelling, loss of function 
and pain are the dominating signs of inflammation because 
of the release of various inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α) (Zelová and Hošek 2013). 
However, prolonged existence of uncontrolled inflamma-
tion gives rise to the development of various diseases such 
as rheumatoid arthritis (RA) (Harth and Nielson 2019). 
TNF-α is abundantly present in RA patients’ serum and the 
arthritic synovium as a primary and major cytokine disturb-
ing the controlled balance between pro- and anti-inflamma-
tory cytokines (Zelová and Hošek 2013). Indeed, TNF-α 
is known to be a potent inducer of other pro-inflammatory 
mediators including interleukin 1β (IL-1β), chemokines, and 
proteases (Farzaei et al. 2019).
Conventionally, the treatment of RA is based upon disease-
modifying anti-rheumatic drugs like methotrexate, which slow 
down joint damage and reduce joint swelling and pain (Fried-
man and Cronstein 2019). However, treatment of RA has been 
revolutionized by the discovery of the role of certain cytokines, 
in particular TNF-α, in the pathogenesis of the disease (Udalova 
et al. 2016). Since the first developments of TNF-α inhibitors 
in RA in the 1980s, drugs as adalimumab, certolizumab pegol, 
etanercept, golimumab, and infliximab have shown improv-
ing clinical, functional, and radiological outcomes in patients 
with RA disease (Abbasi et al. 2019). However, all anti-TNF-α 
agents have produced common adverse effects (occurring in 
more than 10% of patients) that include headaches, injection 
site reaction with the subcutaneous route and infusion reaction 
with the intravenous route of administration, rashes, anemia, 
transaminitis (usually mild), upper respiratory tract infections, 
sinusitis, cough, pharyngitis, diarrhea, nausea, and abdominal 
pain (Puxeddu et al. 2016). Therefore, it has become important 
and essential to develop safer and more cost-effective TNF-α 
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inhibitors. In nature, many natural compounds belonging to 
various classes have been found to reduce TNF-α levels (Ye 
et al. 2016). These natural compounds have been found to inter-
fere with various pro-inflammatory mediators, such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and other signaling molecules, involved in TNF-α expression 
and, thus, they could provide an alternative means of treat-
ing RA, modulating the production, rather than the activity of 
TNF-α (Doss et al. 2016).
The genus Syzygium is one of 131 genera (about 1200 
species) belonging to the family Myrtaceae which are native 
to the tropics, particularly, in tropical America and Asia 
(de Paulo Farias et al. 2020). Many species of this genus 
are used popularly to treat digestive tract disorders, den-
tal pain, and arthritis (Chua et al. 2019). Syzygium jambos 
(L.) Alston commonly known as “rose apple” is a medici-
nal plant widely used in Guatemala, but is also found in 
Bangladesh, Nepal, Malaysia, and sub-Saharan Africa (Hos-
sain et al. 2016). The decoction of the fruit and leaves are 
traditionally used for its antipyretic and anti-inflammatory 
properties, such as gastrointestinal disorders, rheumatism, 
and tooth ailments and to relieve sore eye conditions (Chua 
et al. 2019).
The pharmacological value of S. jambos has been docu-
mented (Haque et al. 2015). Generally, leaf aqueous and 
alcoholic extracts have shown a promising anti-inflammatory 
activity (Hossain et al. 2016). Chemical investigation of the 
active extracts revealed several secondary metabolites. For 
instance, flavonoids, tannins, and triterpenoids (Sobeh et al. 
2018). Slowing et  al. (1994) suggested that myricetin 
3-O-xylosyl-(1 → 2) rhamnoside and quercetin were the main 
compounds responsible for the anti-inflammatory action of 
this medicinal plant. Accordingly, the present work was car-
ried out to evaluate the anti-inflammatory and anti-arthritic 
activities of the aqueous extract of S. jambos and two of its 
isolated glycosylated flavonoids (1 and 2) in the edematogenic 
agent-induced mice paw inflammation.
Materials and Methods
General Experimental Procedures
Thin-layer chromatography was performed using Merck 
silica gel 60-F254 plates, which were visualized by UV 
absorbance (254 nm). Developed plates were stained with 
phosphomolybdic acid  (H3PMo12O40) solution in ethanol 
for detection through heating. Open column chromatogra-
phy was performed with silica gel (20–45 and 40–63 μm). 
Nuclear magnetic resonance (NMR) experiments were 
performed on a Bruker Analytische Messtechnik GmbH 
spectrometer operating at 250 MHz (1H) or 75 MHz (13C) 
and Bruker BioSpin GmbH operating at 300 MHz (1H) or 
76 MHz (13C). Spectra were calibrated by assignment of 
the residual solvent peak to δH 7.26 ppm and δC 77.16 ppm 
for  CDCl3, δH 3.31 ppm and δC 49 ppm for MeOD, and δH 
4.79 ppm for  D2O.
Plant Material
The leaves of Syzygium jambos (L.) Alston, Myrtaceae, 
were collected at the Chimaltenango Municipality, Gua-
temala (14° 40′ 21.4″ N, 90° 47′ 53.7″ W) at an altitude of 
1800 m. The botanical identification was confirmed by Dr. 
Antonio Galán, the Botany Department Herbarium of the 
Faculty of Pharmacy (Universidad Complutense), where a 
sample was deposited (herbarium number 136091).
Isolation
The air-dried leaves (100 g) were extracted by decoction 
(30 min at boiling point) with distilled water (900 g). The 
resulting aqueous extract was frozen in glass containers 
at a temperature of – 38 °C and then lyophilized (Freeze 
dryer, Christ alpha 1e2 LD plus, Germany) at – 50 °C. 
Subsequently, the residue (80 g) was further extracted with 
n-heptane (n-C7H16),  CH2Cl2/MeOH (1:1), and  H2O. As a 
result, three fractions were obtained: 5 g n-C7H16 fraction, 
35 g  CH2Cl2/MeOH fraction, and 30 g aqueous fraction. 
Each fraction was evaluated for its cytotoxicity and anti-
inflammatory activities.
The  CH2Cl2/MeOH fraction (30 g) was the most active 
and further fractionated using a chromatographic column 
(silica gel; 40–63 μm) using a step gradient of n-C7H16/
EtOAc (7:1 → 3:1) to produce ten fractions (I–X). Fractions 
VIII (3.7 g) and IX (2.8 g) were observed to be the most 
active fractions (anti-inflammatory activity). The chroma-
tographic profile analysis of these fractions showed that 
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they were similar, so they were pooled. A second a chro-
matographic column (silica gel; 20–45 μm) was performed 
using a step gradient n-C7H16/EtOAc (3:1 → 0:3). Five 
sub-fractions (1–5) were obtained and all of them showed 
anti-inflammatory activity, but sub-fractions 4 (1 g) and 5 
(0.75 g) were the most active. The chromatographic pro-
file of sub-fractions 4 and 5 showed that they were pure 
(> 99%). They were identified as being quercetin-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (1; Rf 0.43, 
EtOAc/Butanone/HCO2H/H2O, 5:3:1:1) and myricetin-3-
O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (2; Rf 
0.36, EtOAc/Butanone/HCO2H/H2O, 5:3:1:1). The percent-
age obtained of each isolated compound from the  CH2Cl2/
MeOH fraction was 0.7% (1) and 0.5% (2).
Quercet in-3-O-β-d-xylofuranosyl-(1 →  2)-α-l-
rhamnopyranoside (1): light yellow solid powder; 1H and 
13C NMR data (Fig. 9S-14S and Table 1S). The 1H and 13C 
NMR spectroscopic data were identical with those previ-
ously described (Slowing et al. 1994).
Myricet in-3-O -β-d-xylofuranosyl-(1 →  2)-α-l-
rhamnopyranoside (2): intense yellow solid powder; 1H and 
13C NMR data (Fig. 15S-18S and Table 1S). The 1H and 13C 
NMR spectroscopic data were identical with those previ-
ously described (Slowing et al. 1994).
Cytotoxicity Assay
For this assay, the protocol developed by Apaza Ticona et al. 
(2021) was used. RAW 264.7 cell proliferation was determinate 
using the commercial Lactate Dehydrogenase kit (LDH, Innoprot 
Company, Bizkaia, Spain). Cells were sub-cultured in 96 well 
culture plates at a density of 1 ≥  104 cells/well in 100 μl of DMEM 
medium and incubated for 24 h at 37 °C. After 24-h incubation, 
the old medium was removed and the cells were filled with 100 μl 
of fresh medium treated with the samples to be analyzed.
Stock solutions of the samples were prepared by dissolv-
ing them in DMSO at a concentration of 20 mg/ml for the 
extract and the fractions, and 10 mM for the compounds. 
Subsequently, from the stock solutions, a series of dilutions 
were performed until a final DMSO concentration of 0.1% 
was obtained in each of the wells of the plate for each of the 
tested concentrations (100, 50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 
0.4, and 0.2 μg/ml or μM). Actinomycin D (≥ 95% Sigma-
Aldrich; CAS Number 50–76-0) was used as a positive 
control at a concentration of 0.01 μg/ml for the extract and 
fractions, equivalent to 0.008 μM for the compounds. The 
treated plates were incubated in a humidified incubator at 
37 °C under a 5%  CO2 atmosphere for 6 h. After the treat-
ment with the samples, 100 μl of culture medium superna-
tants was collected and incubated in the reaction mixture of 
the LDH kit. After 30 min, the reaction was stopped by the 
addition of 1 N HCl, and the absorbance at a wavelength of 
490 nm was measured using a spectrophotometric ELISA 
(enzyme-linked immunosorbent assay plate reader, Spec-
traMax® i3, Molecular Devices, CA, USA).
Inhibition of TNF‑α Production
The protocol developed by Tena Pérez et al. (2020) was used 
for this assay. RAW 264.7 cell (1 ×  104 cells/well) were 
seeded on a 96-well culture plates and incubated for 6 h. 
The cells were then treated with the extracts, fractions, and 
compounds at the same concentrations used in the viabil-
ity assays for 2 h, before stimulation with 0.1 μg/ml of the 
LPS (lipopolysaccharide) with or without samples for 6 h. 
Supernatants were then collected, and the protein expres-
sion levels of TNF-α were measured by using an ELISA 
kit, according to the manufacturer’s instructions (Diaclone 
Company, Besancon, France). Absorbance was read at 
450 nm on a spectrophotometric ELISA plate reader (Anthos 
2020, version 2.0.5, Biochrom Ltd., UK). The percentage 
of TNF-α inhibition was calculated from the ratio between 
the observed TNF-α amount secreted by treated cells (μg/
ml or μM) and the baseline secretion of TNF-α (pg/ml). C87 
(3-phenyl-1-(4-phenyl-2-thiazolyl)-1H-pyrazole-4,5-dione-
4-[2-(4-chloro-3-nitrophenyl)-hydrazone]; ≥ 98% Sigma-
Aldrich; 332,420–90-3) was used as positive control at a 
concentration of 0.055 μg/ml for the extract and fractions, 
equivalent to 0.11 μM for the compounds. Results were nor-
malized to the DMSO solvent control (1%).
Anti‑inflammatory Activity
Measurement of Paw Edema
The anti-inflammatory activity of the aqueous extract, 
fractions, and isolated compounds was evaluated by the 
method of carrageenan-induced inflammation in the ante-
rior paw of the mice as described by Apaza Ticona et al. 
(2021). Seven groups (5 mice for group) were selected for 
this study. Group 1 served as negative control and received 
normal saline solution at a dose of 5 ml/kg (p.o.), group 2 
received λ-carrageenan (CARR, Sigma-Aldrich; CAS Num-
ber 9064–57-7) (300 μg/paw, 50 μl of 0.9% saline solution), 
and group 3 received indomethacin (IND, 98.5–100.5% 
Sigma-Aldrich; CAS Number 53–86-1) 5 mg/kg (p.o.) and 
served as the positive control; while for groups 4–7, they 
were treated with aqueous extracts (5 mg/kg, p.o.), fractions 
(5 mg/kg, p.o.), and compounds (5 mg/kg, p.o.). The dose 
of 5 mg/kg (p.o.) was selected for the treatments of extracts, 
fractions, and compounds based on the protocol of Apaza 
Ticona et al. (2021) to compare the anti-inflammatory effect 
with the positive control. After 30 min of the intraperitoneal 
treatment of the animals of groups 3–7 with IND and the 
samples (extract, fractions, and compounds), the inflamma-
tion was induced by the injection of 50 μl of CARR solution 
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(type IV Sigma Chemical Company, USA) into the right 
hind paw of each mouse. The thickness of the paw edema 
was measured immediately after CARR injection and during 
the 6 h following the induction of the edema at an interval of 
1 h after the administration of the edematogenic agent using 
a plethysmometer (model 520, IITC Life Science, Woodland 
Hills, CA). All the assessments were performed by the same 
investigator in order to reduce any potential inter-operator 
differences. The size of the edema was calculated as follows:
Xt  size of the paw edema after edematogenic agent 
(CARR) injection at “t”.
X0  size of the paw edema before edematogenic agent 
(CARR) injection.
The anti-inflammatory activity was calculated as a per-
centage of inhibition of edema by the extract in treated ani-
mals under test in comparison with the CARR control group.
X  Increase in paw edema of the CARR group
Y  Increase in paw edema of the treated group
The animals were sacrificed after 6 h. The CARR-induced 
edema feet were dissected and stored at – 70 °C. Blood sam-
ples were taken from anesthetized mice 6 h after the CARR 
administration and kept at – 70 °C. According to the type of 
assay, samples were taken: in citrate tubes to be centrifuged 
for 15 min at 1792 relative centrifugal force (RCF) obtain-
ing a plasma isolate to analyze TNF-α, in heparin tubes to 
be centrifuged for 15 min at 1792 RFC obtaining a plasma 
isolate to analyze C-reactive protein (CRP), and in citrate 
tubes to be centrifuged for 15 min at 1792 RFC obtaining a 
plasma isolate to analyze fibrinogen.
Measurement of Inflammatory Parameters
The serum levels of TNF-α were determined using an ELISA 
kit, using the manufacturer’s instructions (Diaclone Com-
pany, Besancon, France). Absorbance was read at 450 nm 
on a spectrophotometric ELISA plate reader (Anthos 2020, 
version 2.0.5, Biochrom Ltd., UK). TNF-α was determined 
from a standard curve. The CRP dosage was determined by an 
automatic analyzer COBAS INTEGRA@ 400 plus analyzer 
C-reactive. The results were automatically calculated in terms 
of concentration. The CRP level is expressed in milligrams per 
liter of serum. The plasma fibrinogen assay was determined 
according the methodology described by Apaza Ticona et al. 







% Inhibition = [((X − Y)∕X)] ∗ 100
tested were loaded into the STA line apparatus, where they 
were diluted by Owren-Koller buffer (pH = 7.35) (the dilutions 
were carried out automatically by the apparatus). Then, the 
reagent STA-Fibrinogen was added. The level of fibrinogens 
in the tested samples is expressed in grams per liter of plasma.
Anti‑arthritic Activity
Measurement of Paw Edema
Experimental arthritis was induced in mice according to the 
method used by Apaza Ticona et al. (2021). Eight groups 
(five mice for group) were selected for this study. Group 1 
served as negative control and received normal saline solu-
tion at a dose of 5 ml/kg (p.o.), group 2 received 0.05 ml 
(s.c.) of Freund’s Complete Adjuvant (CFA, Sigma-Aldrich; 
MDL number MFCD00131105) (CFA, 1% suspension in 
olive oil; Difco), and group 3 received IND (5 mg/kg, p.o.) 
in 1% carboxymethylcellulose as a positive control. Mice 
in groups 4–7 were treated with the aqueous extract (5 mg/
kg, p.o.), fractions (5 mg/kg, p.o.), and isolated compounds 
(5 mg/kg, p.o.) 24 h before of the injection of CFA and, then, 
with a daily treatment until 14 days after CFA challenge. The 
edema and inflammatory parameters were measured with the 
same methods described above.
Statistical Analysis
CC50 (cytotoxic concentration 50%) and  IC50 (inhibitory 
concentration 50%) values were determined by non-linear 
regression. All the experiments were performed in triplicate. 
For the results of the inflammatory assays in plantar edema, 
the data are presented as means ± S.E.M., except for the  ID50 
values, which are reported as geometric means accompa-
nied by their respective 95% confidence limits. Two-way 
ANOVA statistical analysis (Šídák’s multiple comparisons 
test **p < 0.01 and ***p < 0.001) was performed to evaluate 
the significant differences among values. All the analyses 
were performed using GraphPad Prism, version 9.0.0. Soft-
ware (CA, USA).
Results and Discussions
RAW 264.7 cells were selected as a useful tool to assay the 
in vitro viability (LDH) and anti-inflammatory (inhibition 
of TNF-α production) of the extract, fractions, and isolated 
compounds from S. jambos. The objective of the present 
investigation was to provide preliminary evidences for the 
ethnopharmacological use of this species as an antipyretic 
and anti-inflammatory cure (rheumatism) (Chua et al. 2019).
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Cytotoxic Effects
First, the viability of the RAW 264.7 cells was evaluated 
after 12 h of treatment with the prepared extract or the frac-
tions. The aqueous extract did not show a statistically signifi-
cant cytotoxic effect  (CC50 = 98.91 μg/ml, p = 0.086) when 
compared to the positive control (ACT,  CC50 = 13.04 μg/
ml) in the RAW 264.7 cell line (Fig. 1S). Regarding the 
cytotoxicity of the assayed fractions, the results showed 
that the n-C7H16  (CC50 = 90.91  μg/ml),  CH2Cl2/MeOH 
 (CC50 = 96.25  μg/ml), and aqueous  (CC50 = 98.01  μg/
ml) fractions did not show a relevant cytotoxicity 
(p = 0.080) when compared to the positive control (ACT, 
 CC50 = 13.04 μg/ml) (nsp = 0.011) (Fig. 1S). However, the 
n-C7H16 fraction decreased the viability of all cell lines 
when compared to the negative control (untreated cells) 
 (CC50 = 99.51 μg/ml, ***p < 0.001) (Fig. 1S). Previously, 
Rocchetti et al. (2019) reported the cytotoxicity of a series 
of methanol extracts of different Syzygium species, mention-
ing that the methanolic extract of S. jambos did not present 
cytotoxicity at a concentration of 100 μg/ml on the MCF-7 
cell line. In our case,  CH2Cl2/MeOH fraction could be com-
pared with this methanol extract of S. jambos, showing no 
high cytotoxicity, due to the chemical composition of the 
extract, being mainly phenolic compounds.
Inhibition of TNF‑α Production
The aqueous fraction showed an inhibition of TNF-α pro-
duction at an  IC50 = 59.36 μg/ml (p = 0.081) when com-
pared to the positive control (C87,  IC50 = 0.052 μg/ml) in 
the RAW 264.7 cell line (Fig. 2S). The results showed that 
the  CH2Cl2/MeOH fraction  (IC50 = 45.15 μg/ml) presented 
a higher inhibitory activity of TNF-α than the n-C7H16 
fraction  (IC50 = 79.55  μg/ml) and the aqueous fraction 
 (IC50 = 87.37 μg/ml) in the RAW 264.7 cell line (Fig. 2S). 
These results show that both fractions have anti-inflamma-
tory activity by inhibiting the cytokine TNF-α, which is 
one of the main pro-inflammatory cytokines involved in the 
pathogenesis of chronic inflammatory diseases. It also trig-
gers the cellular release of other cytokines, chemokines, or 
inflammatory mediators (Zelová and Hošek 2013).
The analysis of the inhibitory activity of TNF-α obtained 
with the different treatments indicated that the differences in 
the  IC50 values are due to their chemical composition. For 
the aqueous fraction, and according to its proton spectrum 
(Fig. 3S), it presents signals corresponding to polyphenolic 
compounds (7.5–6.5 ppm) (Apaza Ticona et al. 2021), poly-
saccharides (5.5–3.5 ppm) (Merkx et al. 2018), fatty acids 
(2.5–1.0 ppm) (Castejón et al. 2016), being the polysaccha-
rides are in higher proportion. In the case of n-C7H16 frac-
tion, the presence of fatty acids (2.5–1 ppm) in the proton 
spectrum (Fig. 4S) is observed in a higher proportion than 
the presence of other types of compounds (polyphenols and 
polysaccharides found in a lower proportion, almost non-
existent); while for the  CH2Cl2/MeOH fraction, its proton 
spectrum (Fig. 5S) indicates the presence of polyphenolic 
compounds (7.5–6.5 ppm) and fatty acids (2.5–1 ppm), with 
fatty acids found in a higher proportion. Finally, in the pro-
ton spectrum of the aqueous fraction (Fig. 6S), signals from 
polyphenolic compounds (7.5–6.5 ppm) and polysaccharides 
(5.5–3.5 ppm) are observed, with polysaccharides being the 
ones found in the highest proportion. From these results, it 
can be concluded that the presence of polyphenolic com-
pounds is relevant for the anti-inflammatory activity.
Effect on the Inflammatory Parameters
As shown in Fig. 1A, the sub-plantar injection of CARR 
induced an edema which thickens slowly. The edema size 
variation follows a polynomial function. In fact, 2 h after 
CARR injection, the size of the edema reached a maximum 
which indicates an acute inflammation; this effect of increas-
ing edema (increase in inflammatory mediators) after 2 h of 
CARR injection has already been reported by other research-
ers (Makni et al. 2019). The treatment with the aqueous 
fraction (5 mg/kg) decreased significantly the paw edema 
circumference size (56.46% of edema inhibition). Likewise, 
the mice treated with the  CH2Cl2/MeOH fraction (5 mg/kg) 
showed higher anti-inflammatory activity (48.98% of edema 
inhibition) compared to the aqueous fraction (35.37%), but 
does not present a statistically significant difference with 
n-C7H16 fraction (46.94%). As expected, the IND-positive 
control (5 mg/kg) also caused a significant inhibition of 
edema of 57.14%.
Regarding the anti-arthritic activity, the sub-plantar 
injection of CFA led the paw to swell gradually for more 
than 14 days. The curves of edema rate versus time could 
be divided into two phases. In the first phase, edema rate of 
the injected footpad increased and reached a peak during 
the first 3 days. Thereafter, the swelling slowly subsided 
until the seventh day when the paw began to swell again 
and peaked in the second week (second phase); this effect 
of increasing edema (increase in inflammatory mediators) 
after 7 days of CFA injection has already been reported by 
other researchers (Gomes et al. 2013). The administration 
of the aqueous fraction (5 mg/kg) inhibited the development 
of joint swelling induced by CFA (51.39%) when compared 
to the 5 mg/kg IND-positive control (63.19%) on the eighth 
day after CFA injection (Fig. 1B). Finally, the mice treated 
with the  CH2Cl2/MeOH fraction (5 mg/kg) showed higher 
anti-arthritic activity (54.86% of edema inhibition) when 
compared to the n-C7H16 fraction (42.36%) and the aque-
ous fraction (35.42%) on the eighth day after the CFA 
injection. These results confirm those reported by Slowing 
et al. (1994), which indicate that the aqueous fraction (10% 
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infusion) was very active in suppressing edema (mouse paw) 
in the acute phase (injection of CARR) as well as in the 
chronic stage (injection of CFA) of swelling.
The sub-plantar injection of CARR led to a significant 
increase in the TNF-α level in serum when reaching the fifth 
hour (***p < 0.001). However, the aqueous extract (5 mg/
kg) decreased the TNF-α level in serum when reaching 
the fifth hour after CARR injection (***p < 0.001) when 
compared to the IND group (5 mg/kg) (Fig. 2A). How-
ever, the sub-plantar injection of CFA led to a significantly 
higher increase in the TNF-α level in serum during the first 
3 days (***p < 0.001). Yet, the aqueous fraction (5 mg/kg) 
decreased the TNF-α level in serum during the first day after 
CFA injection (***p < 0.001) when compared to the IND 
group (5 mg/kg) (Fig. 2B).
In relation to the CRP level and the fibrinogen rate, 
a highly significant increase was observed in the CARR 
group when compared to the control group (***p < 0.001). 
Yet, the CRP level significantly decreased (***p < 0.001) 
in the groups treated with the aqueous fraction (12.21 mg/
ml),  CH2Cl2/MeOH fraction (9.71  mg/ml), and IND 
(13.07  mg/ml) when compared to the CARR group 
(24.08  mg/ml) (Fig.  3A). Also, the fibrinogen rate 
decreased significantly (***p < 0.001) in the groups 
treated with the aqueous fraction (4.14  g/l),  CH2Cl2/
MeOH fraction (3.86 g/l), and IND (3.38 g/l) when com-
pared to the CARR group (5.14 g/l) (Fig. 3B). Finally, 
when compared to the control group, a highly significant 
increase was observed in the CFA group (***p < 0.001) 
regarding the CRP level and the fibrinogen rate. Yet, 
in the groups treated with the aqueous fraction (23 mg/
ml),  CH2Cl2/MeOH fraction (17.78  mg/ml), and IND 
(27.60 mg/ml), the CRP levels significantly decreased 
(***p < 0.001) when compared to the CFA group 
(34.25  mg/ml) (Fig.  4A). Additionally, the fibrinogen 
rate decreased significantly (***p < 0.001) in the groups 
treated with the aqueous fraction (13.98 g/l), with the 
 CH2Cl2/MeOH fraction (12.74 g/l) and IND (12.22 g/l) 
when compared to the CFA group (16.64 g/l) (Fig. 4B).
Based on the analysis of the proton spectra of aqueous 
extract and  CH2Cl2/MeOH fraction (Fig. 3S and 5S), we can 
indicate that the signals between 7.5 and 6.5 ppm correspond 
to polyphenolic compounds (flavonoids) (Apaza Ticona 
et al. 2021). These extracts rich in polyphenolic compounds 
may have anti-inflammatory activity (Bezerra et al. 2017). 
In our case, based on the literature and the assays that we 
carried out, we can indicate that its mechanism of action is 
inhibition of TNF-α by downregulation gene expression for 
NF-κB.
Effects of compounds 1 and 2
The cytotoxic effect of compounds 1 and 2 was evalu-
ated by the LDH assay in RAW 264.7 cells for 12 h. The 






















































Fig. 1  Edema size evolution over time in the different groups of 
mice treated with the aqueous extract  (Aq.E) and fractions (HEP.
F=n-C7H16, DCM/MeOH.F=CH2Cl2/MeOH and Aq.F=H2O) 
from  Syzygium jambos. Control (untreated control mice). Each 
value represents the mean ± SEM of results  from six animals. 
(**p<0.01 and ***p<0.001) highly significant difference in com-
parison with  inflamed mice treated with indomethacin (IND 
group). Two-way ANOVA followed by Šídák's  multiple compari-
sons test for CARR=carrageenan (A) with a F (1.167, 4.668) and 
CFA=Freund’s Complete Adjuvant (B) with an F (1.060, 4.242)
































































































Fig. 2  The effects of the aqueous extract (Aq.E) and fractions (HEP.
F=n-C7H16,  DCM/MeOH.F=CH2Cl2/MeOH and Aq.F=H2O) from 
Syzygium jambos on TNF-α induced by  CARR=carrageenan (A) 
and CFA=Freund’s Complete Adjuvant (B). Control (untreated con-
trol mice). Each value represents the mean ± SEM of results from six 
animals. (**p<0.01 and  ***p<0.001) highly significant difference 
in comparison with inflamed mice treated with  indomethacin (IND 























































































Fig. 3  Study of CRP (C-reactive protein) levels (A) and fibrinogen 
(B) in mice treated with the  aqueous extract (Aq.E) and fractions 
(HEP.F=n-C7H16, DCM/MeOH.F=CH2Cl2/MeOH and  Aq.F=H2O) 
from Syzygium jambos induced by CARR (carrageenan). Values rep-
resent the mean ± SD (??=6) in each group
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compounds were less cytotoxic than the ACT, used as a 
positive control  (CC50 = 0.00798 μM) in all the tested cell 
lines (***p < 0.001). Compounds 1  (CC50 = 86.61 μM) and 
2  (CC50 = 85.63 μM) did not show a statistically significant 
difference (nsp = 0.075) when compared to the negative con-
trol (untreated cells) (Fig. 5). These compounds inhibited the 
production of the TNF-α in RAW 264.7 cell line with  IC50 
of 1.68 (1) and 1.11 μM (2), respectively, when compared to 
the positive control (C87,  IC50 = 0.11 μM) (Fig. 7S).
In Fig. 8S, the sub-plantar injection of CARR induced 
an edema whose size variation follows a polynomial func-
tion. The size of the edema reached its maximum expres-
sion (acute inflammation) within 2 h after CARR injec-
tion. In this sense, treatment with compound 1 (5 mg/kg) 
decreased the size of the circumference of the paw edema 
(53.59% inhibition of edema). Likewise, mice treated with 
compound 2 (5 mg/kg) showed higher anti-inflammatory 
activity (61.44% inhibition of edema) when compared to 
the IND-positive control (5 mg/kg) that inhibited the edema 
by 55.56%.
Regarding the anti-arthritic activity, the sub-plan-
tar injection of CFA led the paw to swell gradually for 
more than 14 days. The edema rate curves were divided 
into two phases as a function of time. In the first phase, 
edema rate of the injected footpad increased and reached 
























































































Fig. 4  Study of CRP (C-reactive protein) levels (A) and fibrinogen 
(B) in mice treated with the  aqueous extract (Aq.E) and fractions 
(HEP.F=n-C7H16, DCM/MeOH.F=CH2Cl2/MeOH and  Aq.F=H2O) 
from Syzygium jambos induced by CFA (Freund’s Complete Adju-
vant). Values represent the mean ± SD (??=6) in each group

























Fig. 5  CC50s of the LDH (cytotoxicity) assays calculated for the 
quercetin-3-O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (1) 
and myricetin-3-O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside 
(2) compounds from Syzygium jambos.  CC50 was calculated using 
Prism v9.0.0 (GraphPad Software) using non-linear regression, dose–
response curves. CI95%: confidence interval 95%/Tukey’s multiple 
comparisons test (**p < 0.01 and ***p < 0.001)
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slowly subsided until the seventh day when the paw began 
to swell again and peaked in the second week (second 
phase), this effect has already been reported by other 
researchers. The administration of compound 1 (5 mg/kg) 
significantly inhibited (65.96%) the development of joint 
swelling induced by CFA when compared to the 5-mg/
kg IND-positive control (58.87%) on the eighth day after 
CFA injection (Fig. 8S). Finally, the mice treated with 
compound 2 (5 mg/kg) showed higher anti-arthritic activ-
ity (66.67% of edema inhibition) on the eighth day after 
the CFA injection.
The compounds decreased the TNF-α level in the 
serum when reaching the fifth hour after the CARR injec-
tion (***p < 0.001). Nevertheless, compounds showed a 
higher decrease TNF-α level in serum when reaching the 
fifth hour after the CARR injection (***p < 0.001) when 
compared to IND group (5 mg/kg) (Fig. 6A). Additionally, 
the compounds (5 mg/kg) decreased the TNF-α level in 
the serum during the first 3 days after the CFA injection 
(***p < 0.001). Yet, compounds decreased the TNF-α level 
in serum after the first day following the injection of CFA 
(***p < 0.001) when compared to the IND group (5 mg/kg) 
(Fig. 6B).
Statistical analysis revealed that compounds 1 and 2 and 
IND significantly inhibited the development of edema in the 
fifth hour after treatment (***p < 0.001). Both showed anti-
inflammatory effects on the paw of mice with edematogenic 
agent-induced edema. Likewise, compounds 1 and 2 and 
IND significantly (***p < 0.001) inhibited the development 
of edema in the first 3 days after injection of CFA in the 
paw of mice.
Flavonoids belong to a group of natural substances with 
variable phenolic structures, found in the form of aglycones, 
glycosides, and methylated derivatives in plants (Rha et al. 
2019). Flavonoids are active redox agents and have been 
reported to possess in vitro and in vivo anti-inflammatory 
activity, through different mechanisms of action such as the 
inhibition of enzymes (phospholipase A2, cyclooxygenases, 
and lipoxygenases), suppression of inflammatory cytokines 
(TNF-α, NF-κB, IL-1β), modulation of transcription factors 
and pathways related to inflammation, and reduced accu-
mulation of nitric oxide (NO) or reactive oxygen species 
(ROS) (Farzaei et al. 2019). Catechols in flavonoids are 
also able to form chelates with metals and are reactive in 
their oxidized form (like quinones) with nucleophiles pre-
sent in lateral protein chains such as cysteine and lysine. 
For example, several in vitro studies have revealed that the 
anti-inflammatory activity (inhibition of NO production and 
iNOS expression) of flavonoids is due to the double bond at 
carbon 2 and hydroxyl substitutions in the ring (Shen et al. 
2002). Likewise, there are flavonoids that attenuate inflam-
mation mediators such as TNF-α in THP-1, RAW 264.7, 
and J774a cells (di Gesso et al. 2015). As stated previously, 
studies have already shown that the inhibition of TNF-α by 























































Fig. 6  The effects of the quercetin-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (1) and  myricetin-3-
O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (2) compounds 
from Syzygium  jambos on TNF-α induced by CARR=carrageenan 
(A) and CFA=Freund’s Complete Adjuvant (B).  Control (untreated 
control mice). Each value represents the mean ± SEM of results from 
six animals. (**p<0.01 and ***p<0.001) highly significant difference 
in comparison with inflamed mice treated  with indomethacin (IND 
group). Values represent the mean ± SD (??=6) in each group
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flavonoids is by downregulating gene expression for NF-κB 
(Ruiz et al. 2007).
Our results showed that compound 2 has a higher anti-
inflammatory effect (inhibition of TNF-α, in vitro) that is 
not statistically significant (p = 0.0431). However, in in vivo 
assays, it is observed that both compounds showed similar 
values in all inflammation parameters. This difference in 
activity, which is not statistically significant in the in vitro 
assay (inhibition of TNF-α), is due to the number of hydrox-
yls, lipophilic capacity, and its metabolism. In relation to 
the number of hydroxyls, although myricetin (compound 2 
in aglycone form) is structurally similar to quercetin (com-
pound 1 in aglycone form), they have different antioxidant 
and anti-inflammatory effects (Wang et al. 2006). Regarding 
lipophilic capacity, the parameter that determines the lipo-
philicity of a molecule is LogP (the partition coefficient of 
the molecule between an aqueous and lipophilic phase, usu-
ally water and octanol). The LogP is a crucial factor govern-
ing passive membrane partitioning; being that an increase in 
LogP enhances permeability (Tena Pérez et al. 2020). In our 
case, compound 2 showed a cLogP of 0.68 that allowed it to 
cross the membrane more easily in relation to compound 1, 
which showed a cLogP of 0.62.
Finally, previous studies have shown that after oral 
administration, quercetin (compound 1 in aglycone form) 
is biotransformed into 3,4-dihydroxyphenylacetic acid; 
3-(3-hydroxyphenyl) propionic acid; 3,4-dihydroxyben-
zoic acid; and 4-hydroxybenzoic acid (Luca et al. 2020). 
However, the myricetin (compound 2 in aglycone form) 
is biotransformed into 3,5-dihydroxyphenylacetic acid; 
3,4,5-trihydroxyphenylacetic acid; methylate myricetin; 
dimethylate myricetin; tetramethylate myricetin; myricetin 
monoglucuronide; and myricetin diglucuronide (Lin et al. 
2012). Therefore, it is necessary to determine if the greater 
number of compounds derived from the biotransformation 
of myricetin can generate a greater anti-inflammatory effect 
in comparison with quercetin.
On the other hand, Antunes-Ricardo et al. (2015) deter-
mined that diglycoside flavonoids have greater anti-inflam-
matory activity (inhibition of NO release) compared to their 
corresponding triglycosides and aglycones. In our case, 
compounds 1 and 2 are linked to the sugars β-d-xylofuranose 
and α-l-rhamnopyranose. This is the first time that their anti-
inflammatory activity has been reported.
Finally, regarding the mechanism of action of the two iso-
lated compounds, even if the inhibition of TNF-α is through 
the downregulation of gene expression for NF-κB, further 
experiments should be performed to determine whether 
these compounds can act on other targets by inhibiting 
inflammatory enzymes, modulating transcription factors and 
inflammation-related pathways, and reducing NO or ROS 
accumulation. In relation to the CRP level, this decreased 
significantly (***p < 0.001) in the groups treated with the 
compounds 1 (15.77 mg/ml) and 2 (9.26 mg/ml) and IND 
(13.37 mg/ml) compared to the CARR group (25.45 mg/
ml) (Fig. 7A). Lastly, with respect the fibrinogen rate, this 
decreased significantly (***p < 0.001) in the groups treated 
with compounds 1 (2.86 g/l) and 2 (2.30 g/l) and IND 
















































Fig. 7  Study of CRP (C-reactive protein) levels (A) and 
fibrinogen (B) in mice treated with the  quercetin-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (1) and  myricetin-3-
O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (2) compounds 
from Syzygium jambos by CARR (carrageenan). Values represent the 
mean ± SD (??=6) in each group
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(3.48 g/l) when compared to the CARR group (5.73 g/l) 
(Fig. 7B). Instead, the CRP level decreased significantly 
(***p < 0.001) in the groups treated with compounds 1 
(19.77 mg/ml) and 2 (16.44 mg/ml) and IND (27.44 mg/ml) 
when compared to the CFA group (35.96 mg/ml) (Fig. 8A). 
Finally, with respect the fibrinogen rate, this decreased sig-
nificantly (***p < 0.001) in the groups treated with com-
pounds 1 (12.32 g/l) and 2 (11.44 g/l) and IND (13.14 g/l) 
when compared to the CFA group (15.78 g/l) (Fig. 8B).
Hematological changes that occur after the administra-
tion of CARR or CFA confirm the resulting acute or chronic 
inflammation. These changes led to an impressive increase 
in blood cells and platelets at the site of inflammation due to 
the release of inflammatory cytokines. Likewise, the inhibi-
tion of inflammation in the mice treated with the compounds 
(5 mg/kg) is confirmed by the significant decrease in fibrino-
gen and CRP levels compared to the mice treated with the 
synthetic drug (IND).
Conclusions
In conclusion, we found that in assays of short dura-
tion, such as carrageenan-induced edema, as well as in 
assays of longer duration, such as CFA-induced arthritis, 
the aqueous extract from S. jambos at a dose of 5 mg/kg 
inhibited significant swelling of the feet of mice. These 
results suggest that this plant has anti-inflammatory effects 
on acute experimental arthritis. Similarly, diglycoside 
flavonoids quercetin-3-O-β-d-xylofuranosyl-(1 → 2)-α-l-
rhamnopyranoside (1)  and myr icet in-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (2) isolated 
have a potent suppressive effect in pro-inflammatory 
responses, proving to be an alternative for the treatment of 
inflammatory diseases. In this sense, our paper contributes 
towards the discovery of compounds capable of modulating 
the activities of TNF-α as possible candidates for the treat-
ment of inflammatory processes.
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Fig. 8  Study of CRP (C-reactive protein) levels (A) and 
fibrinogen (B) in mice treated with the  quercetin-3-O-β-d-
xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (1) and  myricetin-3-
O-β-d-xylofuranosyl-(1 → 2)-α-l-rhamnopyranoside (2) compounds 
from Syzygium jambos by CFA (Freund’s Complete Adjuvant). Val-
ues represent the mean ± SD (??=6) in each group
 Revista Brasileira de Farmacognosia
1 3
Protection of Animal Subjects Experiments reported in this study were 
performed after approval of protocol no. 127 by the Institutional Eth-
ics Committee of Universidad Autónoma de Madrid on June 13, 2020, 
and were carried out in accordance with the “Principles of Laboratory 
Animal Care” from NIH publication 85–23.
Conflict of Interest The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, 
Mohammadi H, Aslani S (2019) Strategies toward rheumatoid 
arthritis therapy; the old and the new. J Cell Physiol 234:10018–
10031. https:// doi. org/ 10. 1002/ jcp. 27860
Antunes-Ricardo M, Gutiérrez-Uribe JA, Martínez-Vitela C, Serna-
Saldívar SO (2015) Topical anti-inflammatory effects of isorham-
netin glycosides isolated from Opuntia ficus-indica. BioMed Res 
Int 2015:847320. https:// doi. org/ 10. 1155/ 2015/ 847320
Apaza Ticona L, Serban AM, Apaza Ticona D, Slowing K (2021) 
Anti-inflammatory and anti-arthritic activities of aqueous extract 
and flavonoids from Tripodanthus acutifolius leaves in mice paw 
oedema. Planta Med Int Open 8:e43–e55. https:// doi. org/ 10. 
1055/a- 1471- 8947
Bezerra AN, Massing LT, de Oliveira RB, Mourão RH (2017) Stand-
ardization and anti-inflammatory activity of aqueous extract of 
Psittacanthus plagiophyllus Eichl. (Loranthaceae). J Ethnophar-
macol 202:234–240. https:// doi. org/ 10. 1016/j. jep. 2017. 03. 029
Castejón D, Fricke P, Cambero MI, Herrera A (2016) Automatic 1H-
NMR screening of fatty acid composition in edible oils. Nutrients 
8:93. https:// doi. org/ 10. 3390/ nu802 0093
Chua LK, Lim CL, Ling A, Chye SM, Koh RY (2019) Anticancer 
potential of Syzygium species: a review. Plant Foods Hum Nutr 
74:18–27. https:// doi. org/ 10. 1007/ s11130- 018- 0704-z
de Paulo FD, Neri-Numa IA, de Araújo FF, Pastore GM (2020) A 
critical review of some fruit trees from the Myrtaceae family as 
promising sources for food applications with functional claims. 
Food Chem 306: 125630. https:// doi. org/ 10. 1016/j. foodc hem. 
2019. 125630
di Gesso JL, Kerr JS, Zhang Q, Raheem S, Yalamanchili SK, O’Hagan 
D, Kay CD, O’Connell MA (2015) Flavonoid metabolites reduce 
tumor necrosis factor-α secretion to a greater extent than their 
precursor compounds in human THP-1 monocytes. Mol Nutr Food 
Res 59:1143–1154. https:// doi. org/ 10. 1002/ mnfr. 20140 0799
Doss HM, Ganesan R, Rasool M (2016) Trikatu, an herbal compound 
ameliorates rheumatoid arthritis by the suppression of inflamma-
tory immune responses in rats with adjuvant-induced arthritis 
and on cultured fibroblast like synoviocytes via the inhibition of 
the NF-κB signaling pathway. Chem-Biol Interact 258:175–186. 
https:// doi. org/ 10. 1016/j. cbi. 2016. 09. 003
Farzaei MH, Singh AK, Kumar R, Croley CR, Pandey AK, Coy-
Barrera E, Kumar Patra J, Das G, Kerry RG, Annunziata G, 
Tenore GC, Khan H, Micucci M, Budriesi R, Momtaz S, Nabavi 
SM, Bishayee A (2019) Targeting inflammation by flavonoids: 
novel therapeutic strategy for metabolic disorders. Int J Mol Sci 
20:4957. https:// doi. org/ 10. 3390/ ijms2 01949 57
Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment 
of rheumatoid arthritis. Jt Bone Spine 86:301–307. https:// doi. org/ 
10. 1016/j. jbspin. 2018. 07. 004
Gomes RP, Bressan E, Silva TM, Gevaerd Mda S, Tonussi CR, Dome-
nech SC (2013) Standardization of an experimental model suitable 
for studies on the effect of exercise on arthritis. Einstein 11:76–82. 
https:// doi. org/ 10. 1590/ s1679- 45082 01300 01000 14
Haque M, Begum MM, Hasan M, Towheedur Rahman AFM, Hussain 
MI, Mizanur Rahman M, Ali MH, Islam MA, Sultan MZ, Reyad-
ul-Ferdous M, Hasan CM (2015) Investigation of the medicinal 
potentials of Syzygium jambos (L.) extract and characterization of 
the isolated compounds. Am J BioSci 3:12–18. https:// doi. org/ 10. 
11648/j. ajbio.s. 20150 30201. 13
Harth M, Nielson WR (2019) Pain and affective distress in arthritis: 
relationship to immunity and inflammation. Expert Rev Clin 
Immunol 15:541–552. https:// doi. org/ 10. 1080/ 17446 66X. 2019. 
15736 75
Hossain H, Rahman SE, Akbar PN, Khan TA, Rahman MM, Jahan IA 
(2016) HPLC profiling, antioxidant and in vivo anti-inflammatory 
activity of the ethanol extract of Syzygium jambos available in 
Bangladesh. BMC Res Notes 9:191. https:// doi. org/ 10. 1186/ 
s13104- 016- 2000-z
Kuprash DV, Nedospasov SA (2016) Molecular and cellular mecha-
nisms of inflammation. Biochem Biokhimiia 81:1237–1239. 
https:// doi. org/ 10. 1134/ S0006 29791 61100 18
Lin Y, Wu B, Li Z, Hong T, Chen M, Tan Y, Jiang J, Huang C (2012) 
Metabolite identification of myricetin in rats using HPLC coupled 
with ESI-MS. Chromatographia 75:655–660. https:// doi. org/ 10. 
1007/ s10337- 012- 2239-z
Luca SV, Macovei I, Bujor A, Miron A, Skalicka-Woźniak K, Aproto-
soaie AC, Trifan A (2020) Bioactivity of dietary polyphenols: the 
role of metabolites. Crit Rev Food Sci Nutr 60:626–659. https:// 
doi. org/ 10. 1080/ 10408 398. 2018. 15466 69
Makni S, Tounsi S, Rezgui F, Trigui M, Bouassida KZ (2019) Emex 
spinosa (L.) Campd. ethyl acetate fractions effects on inflamma-
tion and oxidative stress markers in carrageenan induced paw 
oedema in mice. J Ethnopharmacol 234:216–224. https:// doi. org/ 
10. 1016/j. jep. 2018. 12. 015
Merkx DWH, Westphal Y, van Velzen EJJ, Thakoer KV, de Roo N, van 
Duynhoven JPM (2018) Quantification of food polysaccharide 
mixtures by 1H NMR. Carbohydr Polym 179:379–385. https:// 
doi. org/ 10. 1016/j. carbp ol. 2017. 09. 074
Puxeddu I, Caltran E, Rocchi V, Del Corso I, Tavoni A, Migliorini P 
(2016) Hypersensitivity reactions during treatment with biological 
agents. Clin Exp Rheumatol 34:129–132
Rha CS, Jeong HW, Park S, Lee S, Jung YS, Kim DO (2019) Antioxi-
dative, anti-inflammatory, and anticancer effects of purified fla-
vonol glycosides and aglycones in green tea. Antioxidants 8:278. 
https:// doi. org/ 10. 3390/ antio x8080 278
Rocchetti G, Lucini L, Ahmed SR, Saber FR (2019) In vitro cytotoxic 
activity of six Syzygium leaf extracts as related to their phenolic 
profiles: an untargeted UHPLC-QTOF-MS approach. Food Res 
Int 126:108715. https:// doi. org/ 10. 1016/j. foodr es. 2019. 108715
Ruiz PA, Braune A, Hölzlwimmer G, Quintanilla-Fend L, Haller D 
(2007) Quercetin inhibits TNF-induced NF-kappaB transcription 
factor recruitment to pro-inflammatory gene promoters in murine 
intestinal epithelial cells. J Nutr 137:1208–1215. https:// doi. org/ 
10. 1093/ jn/ 137.5. 1208
Shen SC, Lee WR, Lin HY, Huang HC, Ko CH, Yang LL, Chen YC 
(2002) In vitro and in vivo inhibitory activities of rutin, wogonin, 
Revista Brasileira de Farmacognosia 
1 3
and quercetin on lipopolysaccharide-induced nitric oxide and 
prostaglandin E2 production. Eur J Pharmacol 446:187–194. 
https:// doi. org/ 10. 1016/ s0014- 2999(02) 01792-2
Slowing K, Sõllhuber M, Carretero E, Villar A (1994) Flavonoid glyco-
sides from Eugenia jambos. Phytochemistry 37:255–258. https:// 
doi. org/ 10. 1016/ 0031- 9422(94) 85036-4
Sobeh M, Esmat A, Petruk G, Abdelfattah MAO, Dmirieh M, Monti 
DM, Abdel-Naime AB, Wink M (2018) Phenolic compounds 
from Syzygium jambos (Myrtaceae) exhibit distinct antioxidant 
and hepatoprotective activities in vivo. J Funct Foods 14:223–231. 
https:// doi. org/ 10. 1016/j. jff. 2017. 12. 055
Tena Pérez V, Apaza Ticona L, Serban AM, Acero GJ, Rumbero 
Sánchez A (2020) Synthesis and biological screening of a library 
of macamides as TNF-α inhibitors. RSC Med Chem 11:1196–
1209. https:// doi. org/ 10. 1039/ D0MD0 0208A
Udalova I, Monaco C, Nanchahal J, Feldmann M (2016) Anti-TNF 
Therapy Microbiol Spectr 4:10. https:// doi. org/ 10. 1128/ micro 
biols pec. MCHD- 0022- 2015
Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ (2006) Distinctive 
antioxidant and anti-inflammatory effects of flavonols. J Agric 
Food Chem 54:9798–9804. https:// doi. org/ 10. 1021/ jf062 0719
Ye H, Wang Y, Jenson AB, Yan J (2016) Identification of inflammatory 
factor TNF-α inhibitor from medicinal herbs. Exp Mol Pathol 
100:307–311. https:// doi. org/ 10. 1016/j. yexmp. 2015. 12. 014
Zelová H, Hošek J (2013) TNF-α signaling and inflammation: inter-
actions between old acquaintances. Inflamm Res 62:641–651. 
https:// doi. org/ 10. 1007/ s00011- 013- 0633-0
